Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.

NCT07233070 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07233070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2025
Completion date
January 31, 2027
Enrollment
210 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke